Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers
Background. For more than 60 years, the synthetic opioid fentanyl has been widely used in anaesthesia and analgesia. While the intravenous formulation is primarily used for general anaesthesia and intensive care settings, the drug’s high lipophilic properties also allow various noninvasive routes of...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Pain Research and Management |
| Online Access: | http://dx.doi.org/10.1155/2021/2887773 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565655653580800 |
|---|---|
| author | S. Nardi-Hiebl J. W. Ndieyira Y. Al Enzi W. Al Akkad T. Koch G. Geldner C. Reyher L. H. J. Eberhart |
| author_facet | S. Nardi-Hiebl J. W. Ndieyira Y. Al Enzi W. Al Akkad T. Koch G. Geldner C. Reyher L. H. J. Eberhart |
| author_sort | S. Nardi-Hiebl |
| collection | DOAJ |
| description | Background. For more than 60 years, the synthetic opioid fentanyl has been widely used in anaesthesia and analgesia. While the intravenous formulation is primarily used for general anaesthesia and intensive care settings, the drug’s high lipophilic properties also allow various noninvasive routes of administration. Published data suggest that intranasal administration is also attractive for use as intranasal patient-controlled analgesia (PCA). A newly developed intranasal fentanyl formulation containing 47 μg fentanyl, intravenous fentanyl, and oral transmucosal fentanyl citrate were characterised, and bioavailability was compared to assess the suitability of the intranasal formulation for an intranasal PCA product. Methods. 27 healthy volunteers were enrolled in a single-centre, open-label, randomised (order of treatments), single-dose study in a three-period crossover design. The pharmacokinetics of one intranasal puff of fentanyl formulation (47 μg, 140 mL per puff), one short intravenous infusion of 50 μg fentanyl, and one lozenge with an integrated applicator (200 μg fentanyl) were studied, and bioavailability was calculated. Blood samples were collected over 12 hours, and plasma concentrations of fentanyl were determined by HPLC with MS/MS detection. Results. 24 volunteers completed the study. The geometric mean of AUC0-tlast was the highest with oral transmucosal administration (1106 h ∗ pg/ml, CV% = 32.86), followed by intravenous (672 h ∗ pg/ml, CV% = 32.18) and intranasal administration (515 h ∗ pg/ml, CV% = 30.10). Cmax was 886 pg/ml (CV% = 59.38) for intravenous, 338 pg/ml (CV% = 45.61) for intranasal, and 310 pg/ml (CV% = 29.58) for oral transmucosal administration. tmax was shortest for intravenous administration (0.06 h, SD = 0.056), followed by intranasal (0.21 h, SD = 0.078) and oral transmucosal administration (1.20 h, SD = 0.763). Dose-adjusted absolute bioavailability was determined to be 74.70% for the intranasal formulation and 41.25% for the oral transmucosal product. In total, 38 adverse events (AEs) occurred. Fourteen AEs were potentially related to the investigational items. No serious AE occurred. Conclusion. Pharmacokinetic parameters and bioavailability of the investigated intranasal fentanyl indicated suitability for its intended use as an intranasal PCA option. |
| format | Article |
| id | doaj-art-82ad051c1fc14b4dad631d453bc34182 |
| institution | Kabale University |
| issn | 1918-1523 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pain Research and Management |
| spelling | doaj-art-82ad051c1fc14b4dad631d453bc341822025-02-03T01:07:07ZengWileyPain Research and Management1918-15232021-01-01202110.1155/2021/2887773Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy VolunteersS. Nardi-Hiebl0J. W. Ndieyira1Y. Al Enzi2W. Al Akkad3T. Koch4G. Geldner5C. Reyher6L. H. J. Eberhart7Department of Anaesthesia and Intensive CareDivision of MedicineDepartment of Mathematics and Natural ScienceRoyal Free London HospitalDepartment of Anaesthesia and Intensive CareDepartment of Anaesthesiology Intensive Care Medicine Emergency Medicine and Pain TherapyDepartment of Anaesthesiology Intensive Care Medicine Emergency Medicine and Pain TherapyDepartment of Anaesthesia and Intensive CareBackground. For more than 60 years, the synthetic opioid fentanyl has been widely used in anaesthesia and analgesia. While the intravenous formulation is primarily used for general anaesthesia and intensive care settings, the drug’s high lipophilic properties also allow various noninvasive routes of administration. Published data suggest that intranasal administration is also attractive for use as intranasal patient-controlled analgesia (PCA). A newly developed intranasal fentanyl formulation containing 47 μg fentanyl, intravenous fentanyl, and oral transmucosal fentanyl citrate were characterised, and bioavailability was compared to assess the suitability of the intranasal formulation for an intranasal PCA product. Methods. 27 healthy volunteers were enrolled in a single-centre, open-label, randomised (order of treatments), single-dose study in a three-period crossover design. The pharmacokinetics of one intranasal puff of fentanyl formulation (47 μg, 140 mL per puff), one short intravenous infusion of 50 μg fentanyl, and one lozenge with an integrated applicator (200 μg fentanyl) were studied, and bioavailability was calculated. Blood samples were collected over 12 hours, and plasma concentrations of fentanyl were determined by HPLC with MS/MS detection. Results. 24 volunteers completed the study. The geometric mean of AUC0-tlast was the highest with oral transmucosal administration (1106 h ∗ pg/ml, CV% = 32.86), followed by intravenous (672 h ∗ pg/ml, CV% = 32.18) and intranasal administration (515 h ∗ pg/ml, CV% = 30.10). Cmax was 886 pg/ml (CV% = 59.38) for intravenous, 338 pg/ml (CV% = 45.61) for intranasal, and 310 pg/ml (CV% = 29.58) for oral transmucosal administration. tmax was shortest for intravenous administration (0.06 h, SD = 0.056), followed by intranasal (0.21 h, SD = 0.078) and oral transmucosal administration (1.20 h, SD = 0.763). Dose-adjusted absolute bioavailability was determined to be 74.70% for the intranasal formulation and 41.25% for the oral transmucosal product. In total, 38 adverse events (AEs) occurred. Fourteen AEs were potentially related to the investigational items. No serious AE occurred. Conclusion. Pharmacokinetic parameters and bioavailability of the investigated intranasal fentanyl indicated suitability for its intended use as an intranasal PCA option.http://dx.doi.org/10.1155/2021/2887773 |
| spellingShingle | S. Nardi-Hiebl J. W. Ndieyira Y. Al Enzi W. Al Akkad T. Koch G. Geldner C. Reyher L. H. J. Eberhart Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers Pain Research and Management |
| title | Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers |
| title_full | Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers |
| title_fullStr | Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers |
| title_full_unstemmed | Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers |
| title_short | Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers |
| title_sort | pharmacokinetic characterisation and comparison of bioavailability of intranasal fentanyl transmucosal and intravenous administration through a three way crossover study in 24 healthy volunteers |
| url | http://dx.doi.org/10.1155/2021/2887773 |
| work_keys_str_mv | AT snardihiebl pharmacokineticcharacterisationandcomparisonofbioavailabilityofintranasalfentanyltransmucosalandintravenousadministrationthroughathreewaycrossoverstudyin24healthyvolunteers AT jwndieyira pharmacokineticcharacterisationandcomparisonofbioavailabilityofintranasalfentanyltransmucosalandintravenousadministrationthroughathreewaycrossoverstudyin24healthyvolunteers AT yalenzi pharmacokineticcharacterisationandcomparisonofbioavailabilityofintranasalfentanyltransmucosalandintravenousadministrationthroughathreewaycrossoverstudyin24healthyvolunteers AT walakkad pharmacokineticcharacterisationandcomparisonofbioavailabilityofintranasalfentanyltransmucosalandintravenousadministrationthroughathreewaycrossoverstudyin24healthyvolunteers AT tkoch pharmacokineticcharacterisationandcomparisonofbioavailabilityofintranasalfentanyltransmucosalandintravenousadministrationthroughathreewaycrossoverstudyin24healthyvolunteers AT ggeldner pharmacokineticcharacterisationandcomparisonofbioavailabilityofintranasalfentanyltransmucosalandintravenousadministrationthroughathreewaycrossoverstudyin24healthyvolunteers AT creyher pharmacokineticcharacterisationandcomparisonofbioavailabilityofintranasalfentanyltransmucosalandintravenousadministrationthroughathreewaycrossoverstudyin24healthyvolunteers AT lhjeberhart pharmacokineticcharacterisationandcomparisonofbioavailabilityofintranasalfentanyltransmucosalandintravenousadministrationthroughathreewaycrossoverstudyin24healthyvolunteers |